[{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"67716777-5690-49d3-993c-981578cca089","acronym":"NUTOBREST","url":"https://clinicaltrials.gov/study/NCT06046755","created_at":"2023-09-21T15:11:09.919Z","updated_at":"2024-07-02T16:35:36.338Z","phase":"","brief_title":"Nutritional Intervention-induced Weight Loss During the Oncological Treatment of Obesity-related Breast Cancer","source_id_and_acronym":"NCT06046755 - NUTOBREST","lead_sponsor":"Hospital Clinico Universitario de Santiago","biomarkers":" TNFRSF8 • TNFA • CD163 • IL6R • IL22 • TSLP • IFNL1 • IFNL2 • MMP3","pipe":"","alterations":" ","tags":["TNFRSF8 • TNFA • CD163 • IL6R • IL22 • TSLP • IFNL1 • IFNL2 • MMP3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 10/15/2023","start_date":" 10/15/2023","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2023-09-21"},{"id":"25fe0366-9fcc-46e6-9e6e-7ecaf7006bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03683147","created_at":"2022-07-25T23:00:13.654Z","updated_at":"2024-07-02T16:36:06.832Z","phase":"","brief_title":"Mindfulness-Based Stress Reduction in Helping Participants With Metastatic Breast Cancer","source_id_and_acronym":"NCT03683147","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • CCL20 • IL10 • IL17A • IL23A • IL1RN • IL21 • IL22 • IFNL2 • IL33"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 12/13/2017","start_date":" 12/13/2017","primary_txt":" Primary completion: 06/19/2019","primary_completion_date":" 06/19/2019","study_txt":" Completion: 04/06/2020","study_completion_date":" 04/06/2020","last_update_posted":"2022-07-25"}]